secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2023-10-06T23:59:59+00:00
Accession:  0001493152-23-036500
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo terminates CEO Simon Allen, appoints Richie Cunningham as new CEO
-------------------------------------------------------------------------

- Simon Allen terminated without cause as CEO; resigned from board effective Oct 5, 2023.
- Richie Cunningham appointed CEO and board member; previously CEO of Tyme Technologies and IXC Discovery.
- Cunningham receives $450k base salary, time-vesting option for 600k shares (16 quarterly installments), and performance-based option for 140k shares.
- Bimal Shah appointed to board and to Audit and Compensation Committees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223036500/0001493152-23-036500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223036500/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-036500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer